August 20, 2024

Meta-analysis Finds Association Between ADHD Medications and Improvements in Executive Functions

ADHD is associated with deficits in cognitive functions. These include such executive functions as reaction time, motor and interference inhibition, sustained attention, and working memory. 

To what extent can ADHD medications compensate for such deficits? A recent meta-analysis by a European study team has explored this question. It suggests that while medication cannot completely reverse deficits in executive functions, it can lead to significant improvements. 

Based on consistent evidence from many randomized double-blind controlled trials (RCTs) measuring behavioral improvements, first line treatment for ADHD is with stimulant medication while second-line treatment (for stimulant non-responders, or poor tolerability) is with non-stimulant medication (atomoxetine, viloxazine, guanfacine and clonidine). 

This systematic literature search yielded eighteen RCTs, not all of which covered the same executive functions or medicines. 

Meta-analyses yielded the following results: 

Reaction Time 

Eleven RCTs, encompassing 925 participants, found a small-to-medium effect size improvement with methylphenidate. Variation (heterogeneity) among these studies was moderate, and there was no sign of publication bias. 

Four RCTs with a total of 286 participants similarly reported a small-to-medium effect size improvement with atomoxetine. Again, heterogeneity was moderate, with no indication of publication bias. 

Attention 

Sixteen RCTs, with a combined 1,335 participants, found a medium effect size improvement with methylphenidate. Heterogeneity was moderate, and there was some indication of publication bias. No effort was made to correct for publication bias. 

Three RCTs, encompassing 254 persons, found a medium effect size improvement with atomoxetine. Heterogeneity was moderate, with no evidence of publication bias. 

Inhibition 

Thirteen RCTs, with a total of 1,201 participants, found a small-to-medium effect size improvement with methylphenidate. Heterogeneity was moderate, with marginal indication of publication bias. 

Six RCTs with a combined 753 individuals, reported a medium effect size improvement with atomoxetine. Heterogeneity was high, but there was no evidence of publication bias. 

Working Memory 

Nine RCTs, with a total of 1,025 participants, found a small-to-medium effect size improvement with methylphenidate. Heterogeneity was moderate, with no indication of publication bias. 

Three RCTs with a combined 132 individuals, reported a statistically nonsignificant small-to-medium effect size improvement with atomoxetine. Heterogeneity was moderate, with no indication of publication bias. The nonsignificant outcome may have been due to the much smaller number of participants. 

‍

The team concluded, “these meta-analyses of chronic effects of stimulants and non-stimulants on executive functions in ADHD showed significant improvements with both methylphenidate and with atomoxetine in all cognitive domains tested with relatively similar effect sizes, and no statistical differences between them. The findings hence suggest comparable positive effects of both ADHD medication types on the most relevant executive functions in ADHD, suggesting for the first time that stimulant and non-stimulant ADHD medications, when taking [sic] longer-term, not only improve behavioural symptoms of ADHD, but also improve executive function performance, and to a similar degree.” 

‍

Ferdous Isfandnia, Sahid El Masri, Joaquim Radua, and Katya Rubia, “The Effects of Chronic Administration of Stimulant and Non-stimulant Medications on Executive Functions in ADHD: A Systematic Review and Meta-Analysis,” Neuroscience and Biobehavioral Reviews (2024), https://doi.org/10.1016/j.neubiorev.2024.105703. 

‍

Related posts

No items found.

Cohort Study Finds ADHD Link to Higher Mortality is Mediated by Comorbid Anxiety and Depression

The Background:

Previous research has suggested that people with ADHD have higher rates of death than those without the condition. Until now, many of those studies lacked the detail needed to untangle why this might be the case. A recent meta-analysis of eight separate studies reported that ADHD roughly doubled the risk of death, and it hinted that factors like socioeconomic status and other mental illnesses might help explain the link.  

The Study: 

To explore this in more detail, researchers used the US National Health Interview Survey, a nationally representative prospective cohort of just over 52,000 adults. Survey records were linked with the National Death Index, and participants were followed from the date of interview until death or December 31, 2019, whichever came first. The main outcome was death from any cause. With a median follow-up of just under eight years, there were 6,024 deaths recorded. 

When the team adjusted their analysis for age, sex, ethnicity, and the year of the survey, having ADHD was associated with a 58% higher risk of death. Controlling further for family income and educational level reduced that increased risk slightly, to 50%. 

Controlling for health conditions (like high blood pressure, diabetes, stroke, heart disease, and cancer) and lifestyle factors (smoking, alcohol use, physical activity, and body weight) also reduced the association to about 46%. 

By contrast, when the researchers adjusted for two psychiatric conditions (anxiety and depression) commonly found alongside ADHD, the link between ADHD and higher mortality disappeared statistically. In other words, once anxiety and depression were taken into account, ADHD itself was no longer associated with a clearly measurable increase in the risk of death. 

What Does This Mean?

The authors conclude that the apparent effect of ADHD on mortality seems to operate largely through accompanying mental illness, and to a lesser extent through lifestyle and physical health problems. They suggest that treating and managing these co-occurring issues (through medications, therapy, and behavioral interventions) might help reduce the risk of premature death in people with ADHD, although they note that further evidence is needed. 

‍

October 14, 2026

Meta-analysis Finds ADHD Associated with Higher-Risk of Dementia

The Background:

Dementia is a rapidly growing public health problem affecting more than 50 million people worldwide. Nearly 10 million new cases are diagnosed each year, and that number is expected to almost triple by 2050. The most common form is Alzheimer’s disease, accounting for roughly 60–70% of cases, followed by vascular dementia at around 20%. Other types include dementia with Lewy bodies, Parkinson’s disease dementia, and frontotemporal dementia. While no cure exists, managing modifiable risk factors (such as high blood pressure, smoking, physical inactivity, and poorly controlled diabetes) can delay or slow both the onset and progression of the condition. 

Several studies have reported an elevated dementia risk among people with ADHD, and a number of mechanisms may explain this association. These include shared genetic or neurobiological vulnerabilities, reduced cognitive reserve (leaving the brain less resilient to age-related damage), and greater lifetime exposure to other established dementia risk factors. 

Earlier reviews explored the possible link between ADHD and dementia, but tended toward a broader scope (incorporating other neurodegenerative disorders or mixing study designs), which introduced substantial variability and precluded quantitative synthesis. The relevant research literature has also expanded considerably since those reviews appeared. 

The Study:

This meta-analysis restricted inclusion to case-control and cohort studies, yielding five that met the criteria. One was a case-control study with 400 participants; the other four were cohort studies collectively covering 3.7 million individuals, two retrospective and two prospective. 

The Results:

Pooling the four cohort studies, individuals with ADHD showed approximately two-and-a-half times the dementia risk of those without the diagnosis. There was no indication of publication bias. 

The Take-Away:

The authors concluded that ADHD is associated with a significantly increased risk of all-cause dementia in later life, while noting that its relationship to specific dementia subtypes remains less clear and warrants attention in future research. 

‍

October 8, 2026

Meta-analysis Finds Association Between Maternal Polycystic Ovary Syndrome (PCOS) and ADHD in Offspring

The Background:

Women with polycystic ovary syndrome (PCOS) themselves show higher rates of ADHD. Because ADHD is partly heritable (meaning genes contribute to the condition), some of the increased ADHD seen in children of mothers with PCOS could come from shared genetic factors. In other words, a mother’s and her child’s increased risk might sometimes reflect common genes rather than an effect of the pregnancy itself. 

Beyond genetics, growing evidence points to maternal metabolic problems during pregnancy as another important risk factor for neurodevelopmental outcomes. PCOS is one of these conditions and is considered both potentially modifiable (treatable or manageable) and biologically plausible as a contributor to risk. PCOS affects an estimated 5–10% of women of reproductive age worldwide and is characterized by signs such as hyperandrogenism (higher-than-normal levels of “male” hormones), insulin resistance (poorer ability to use the hormone insulin, which can affect blood sugar and metabolism), and chronic low-grade inflammation. 

However, studies to date have not all reached the same conclusions. Some research suggests the association between maternal PCOS and offspring ADHD is stronger for girls, while other studies did not analyze results by child sex. Methodological differences make it harder to draw clear conclusions. 

The Study:

It’s important to note that the studies included in this meta-analysis were observational (cohort studies and case-control studies). Observational studies can identify associations (that two things occur together) but cannot prove that one causes the other. A cohort study follows people over time, and a case-control study compares people with a condition to similar people without it. 

The pooled results came from six studies that together included almost 1.4 million mother–child pairs and that adjusted for confounders (other factors that might influence the result, such as maternal age or socioeconomic status). After statistical adjustment, children of mothers with PCOS had about 40% greater odds of ADHD than children of mothers without PCOS. The analysis reported no evidence of publication bias (no clear sign that only positive studies were published) and zero heterogeneity (the results were consistent across the studies). 

There was no meaningful difference in results between cohort and case-control studies, and the meta-analysis did not find a significant difference in the association when comparing male and female offspring. 

The Take-Away:

The research team concluded that this large-scale synthesis found an association between maternal PCOS and higher odds of ADHD and other neuropsychiatric conditions in children. They suggested that children born to mothers with PCOS may benefit from developmental monitoring to identify and address problems early, while emphasizing that causal relationships have not been established. They called for further studies to confirm these findings and to investigate the biological and environmental mechanisms that might explain the association. Indeed, because women with PCOS show higher rates of ADHD than other women, we need genetically informed research designs to see if the reported association is confounded.

‍

October 1, 2026